Biogen Inc (BIIB) Stock Price, Quote & News

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referenc...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 617 679 2000

Website: www.biogen.com

Address:

225 Binney Street, Cambridge, United States

SharpEntry_ Aug. 5 at 2:31 PM

Today's Trading Watchlist $AVAV - Hold $170, targets $184 and $193. $AVGO - Trigger over $422, target $440. $BB - Trigger over $8.95, target $10. $BE - Trigger over $236, targets $254 and $268. $BIIB - Trigger over $209, target $216. Keeping these names on radar as price action decides the next move. Focus is on confirmation, not chasing.

1 · Reply

BrendaSaxe1022 Aug. 5 at 6:48 AM

$CFG $GFI $BIIB $RDDT $ILMN Citizens Financial strengthens banking operations, Gold Fields benefits from higher gold prices, Biogen advances neurological therapies, Reddit continues improving advertising monetization, and Illumina leads genomic sequencing.

0 · Reply

GabrielBarrett973 Aug. 5 at 5:32 AM

$CNC $LVS $AEE $SUNB $BIIB Centene benefits from managed healthcare growth, Las Vegas Sands gains from casino demand, Ameren provides regulated utility exposure, SUNB remains execution-driven, and Biogen advances neurological therapies.

0 · Reply

jdlman Aug. 4 at 4:36 PM

$INCY $BIIB ..shut up josh brown .. always says it after the fact

1 · Reply

Quantumup Aug. 4 at 11:37 AM

Canaccord Genuity y'day⬇️ $STOK to $58 from $60 and reiterated Buy after STOK reported its 2Q26 results. $BIIB PRAX DRUG HLUBF HLBBF $IONS HRMY OVID SUPN UCBJY JAZZ Here's what Canaccord Genuity said in its note to investors: https://x.com/Quantumup1/status/2084604516561756445?s=20

0 · Reply

IN0V8 Aug. 3 at 3:47 PM

$BIIB Citigroup raises target price to $215 from $200

0 · Reply

AnthonyCottrell683 Aug. 3 at 2:47 PM

0 · Reply

Ziggy2359 Aug. 2 at 9:14 PM

$BIIB I'm still checking in on this one

0 · Reply

flychicken1991 Aug. 1 at 4:07 PM

$BIIB Positive (78%): BIIB’s stock price is likely pushed higher by the reported revenue beat and adjusted EPS surprise, although the incremental move could be limited if the market already reacted to the original earnings release. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/a76cfb17fb16349b?utm_source=stocktwits&utm_medium=story_url

0 · Reply

GoforProMIS Jul. 30 at 11:28 AM

$PMN is it $BIIB $LLY or is it $RHHBY for Alzheimer Disease ?

0 · Reply

Biogen price target raised to $241 from $221 at Mizuho

2026-08-03T10:42:26.000Z - 2 days ago

Biogen price target raised to $215 from $200 at Citi

2026-07-30T16:11:19.000Z - 6 days ago

Biogen price target raised to $231 from $222 at Morgan Stanley

2026-07-30T14:20:26.000Z - 6 days ago

Biogen price target raised to $251 from $237 at H.C. Wainwright

2026-07-30T13:50:39.000Z - 6 days ago

Biogen price target lowered to $240 from $242 at RBC Capital

2026-07-30T13:23:31.000Z - 6 days ago

Biogen price target raised to $240 from $225 at UBS

2026-07-30T12:37:52.000Z - 6 days ago

Biogen price target raised to $215 from $201 at Wedbush

2026-07-30T12:05:53.000Z - 6 days ago

Biogen price target raised to $219 from $215 at BofA

2026-07-30T11:32:48.000Z - 6 days ago

Biogen price target raised to $225 from $215 at TD Cowen

2026-07-30T11:06:00.000Z - 6 days ago

Biogen price target raised to $248 from $245 at Canaccord

Jul 29, 2026, 8:30 AM EDT - 7 days ago

Biogen Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 7 days ago

Biogen Slides: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 7 days ago

Biogen Earnings release: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 7 days ago

Biogen Quarterly report: Q2 2026

Jul 29, 2026, 6:23 AM EDT - 7 days ago

Biogen Cuts FY Adjusted View as Profit Declines

2026-07-29T10:16:45.000Z - 7 days ago

Biogen lowers FY26 EPS view to $12.00-$13.00 from $14.25-$15.25

2026-07-29T10:11:40.000Z - 7 days ago

Biogen reports Q2 EPS $3.60, consensus $2.05

Jul 29, 2026, 6:03 AM EDT - 7 days ago

Biogen beats quarterly estimates as newer drugs fuel growth

Jul 29, 2026, 6:02 AM EDT - 7 days ago

Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs

2026-07-29T09:10:46.000Z - 7 days ago

Biogen price target raised to $200 from $185 at Barclays

2026-07-21T12:06:03.000Z - 15 days ago

Biogen price target raised to $280 from $260 at Guggenheim

2026-07-21T11:25:27.000Z - 15 days ago

Biogen price target lowered to $215 from $217 at BofA

Jul 16, 2026, 7:47 AM EDT - 20 days ago

Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

2026-07-15T12:55:40.000Z - 21 days ago

Biogen appoints Michael Parini as chief legal officer

Jul 15, 2026, 8:15 AM EDT - 21 days ago

Biogen Appoints Michael J. Parini as Chief Legal Officer

Jul 14, 2026, 12:00 PM EDT - 22 days ago

Biogen Transcript: Alzheimer’s Association International Conference (AAIC Meeting) 2026

Jul 14, 2026, 12:00 PM EDT - 22 days ago

Biogen Slides: FY 2026

2026-07-14T15:50:29.000Z - 22 days ago

RBC says Biogen detailed Phase 2 results ‘leave more questions than answers’

Jul 14, 2026, 11:15 AM EDT - 22 days ago

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

Jul 14, 2026, 9:18 AM EDT - 22 days ago

Biogen's Alzheimer's drug lowers toxic protein, but results were mixed

Jul 14, 2026, 9:15 AM EDT - 22 days ago

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease

Jul 13, 2026, 5:36 PM EDT - 22 days ago

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

Jul 13, 2026, 3:02 PM EDT - 22 days ago

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

Jul 13, 2026, 8:15 AM EDT - 23 days ago

Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details

Jul 12, 2026, 11:15 AM EDT - 24 days ago

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026

Jul 1, 2026, 7:18 AM EDT - 5 weeks ago

Old cancer drug may help restore fertility for certain women

Jun 29, 2026, 6:59 AM EDT - 5 weeks ago

Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Jun 26, 2026, 9:25 AM EDT - 5 weeks ago

Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout

APLS

Jun 17, 2026, 7:10 PM EDT - 6 weeks ago

Biogen to acquire RayThera for $1 billion

Jun 17, 2026, 6:59 PM EDT - 6 weeks ago

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Jun 17, 2026, 12:30 PM EDT - 7 weeks ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Jun 9, 2026, 2:07 PM EDT - 2 months ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY CVS PFE VZ

Jun 9, 2026, 9:00 AM EDT - 2 months ago

Biogen Transcript: AGM 2026

Jun 4, 2026, 7:30 AM EDT - 2 months ago

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Jun 4, 2026, 1:00 AM EDT - 2 months ago

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Jun 3, 2026, 7:30 AM EDT - 2 months ago

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Jun 3, 2026, 3:30 AM EDT - 2 months ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

ABBV LLY ROP

Jun 1, 2026, 1:30 AM EDT - 2 months ago

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

May 27, 2026, 2:27 AM EDT - 2 months ago

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

May 21, 2026, 6:17 PM EDT - 2 months ago

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

May 21, 2026, 6:00 PM EDT - 2 months ago

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

May 14, 2026, 12:10 PM EDT - 2 months ago

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

May 14, 2026, 9:07 AM EDT - 2 months ago

Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

May 14, 2026, 8:35 AM EDT - 2 months ago

Biogen Completes Acquisition of Apellis Pharmaceuticals

May 14, 2026, 7:03 AM EDT - 2 months ago

Biogen's Alzheimer's drug fails to meet mid-stage trial goal

May 14, 2026, 6:59 AM EDT - 2 months ago

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease

May 13, 2026, 2:20 PM EDT - 2 months ago

Biogen Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 2:30 AM EDT - 3 months ago

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

May 7, 2026, 6:01 PM EDT - 3 months ago

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

APLS BFAM RELY TPH

May 7, 2026, 4:01 PM EDT - 3 months ago

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

STOK

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Biogen Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Biogen Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Biogen Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Biogen Quarterly report: Q1 2026

Apr 29, 2026, 7:02 AM EDT - 3 months ago

Biogen Lowers 2026 Earnings Outlook

Apr 29, 2026, 6:07 AM EDT - 3 months ago

Biogen cuts annual profit forecast on acquisition-related charges

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Biogen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Biogen Proxy statement: Proxy filing

Apr 20, 2026, 9:02 AM EDT - 3 months ago

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma

Apr 20, 2026, 7:30 AM EDT - 3 months ago

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

Apr 18, 2026, 9:00 AM EDT - 3 months ago

These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

LLY

SharpEntry_ Aug. 5 at 2:31 PM

1 · Reply

BrendaSaxe1022 Aug. 5 at 6:48 AM

0 · Reply

GabrielBarrett973 Aug. 5 at 5:32 AM

0 · Reply

jdlman Aug. 4 at 4:36 PM

$INCY $BIIB ..shut up josh brown .. always says it after the fact

1 · Reply

Quantumup Aug. 4 at 11:37 AM

0 · Reply

IN0V8 Aug. 3 at 3:47 PM

$BIIB Citigroup raises target price to $215 from $200

0 · Reply

AnthonyCottrell683 Aug. 3 at 2:47 PM

0 · Reply

Ziggy2359 Aug. 2 at 9:14 PM

$BIIB I'm still checking in on this one

0 · Reply

flychicken1991 Aug. 1 at 4:07 PM

0 · Reply

GoforProMIS Jul. 30 at 11:28 AM

$PMN is it $BIIB $LLY or is it $RHHBY for Alzheimer Disease ?

0 · Reply

RunnerSignals Jul. 29 at 7:54 PM

upgrade scoreboard $BIIB $MU $INTC $AAL drew fresh bullish calls, but only one paired the upgrade with real volume confirmation. read the full breakdown. https://stocksrunner.com/news/2026-07-29-wall-street-analyst-upgrades-to-watch

1 · Reply

JavierSchroeder968 Jul. 29 at 4:56 PM

$BIIB ’s CEO says the company has built enough assets to focus on execution rather than aggressive M&A. After years of business development activity, the next phase is about maximizing existing opportunities, advancing the pipeline, and improving growth from within.

0 · Reply

notreload_ai Jul. 29 at 3:45 PM

$BIIB reports $2.74B Q2 revenue, up 3% and beating estimates. Growth products surge 24%, rare-disease drugs rise 11%. https://notreload.xyz/xy/biogen-beats-q2-estimates-as-newer-drugs-drive-growth/

0 · Reply

endrow Jul. 29 at 3:13 PM

$ACOG OpalEye surely bought up 15% of this company just for fun. They only have the best FDA approved oral Alzheimer's drug on the market afterall, and a less than $200 million market cap. Nothing to see here! $LLY $BIIB $AVXL

0 · Reply

EarningsInsider Jul. 29 at 2:02 PM

https://www.marketbeat.com/earnings/reports/2026-7-29-biogen-inc-stock/ $BIIB Biogen Earnings Transcript

0 · Reply

DonCorleone77 Jul. 29 at 1:08 PM

$STX $F $DB $BIIB $LMND PRE-MARKET MOVERS: Currently Higher After Earnings: - Manhattan Associates (MANH) up 12.9% - Rocky Brands (RCKY) up 12.3% - Generac (GNRC) up 9.4% - Amphenol (APH) up 6.8% - Teva (TEVA) up 5.8% - Seagate (STX) up 5% - Ford (F) up 5.6% - Deutsche Bank (DB) up 2.1% - Biogen (BIIB) up 1.9% Currently Lower After Earnings - Lemonade (LMND) down 16.3% - Vertiv (VRT) down 9.7% - VF Corp. (VFC) down 8.5% - Skyworks (SWKS) down 9.5% - Humana (HUM) down 2.6% - Procter & Gamble (PG) down 3.8% - NXP Semiconductors (NXPI) down 2.2% - WM (WM) down 2.4% - SK Hynix (SKHY) down 1.7% - Visa (V) down 2.1% - OneMain (OMF) down 0.7%.

0 · Reply

OpenOutcrier Jul. 29 at 12:00 PM

$BIIB (+0.7% pre) Biogen Raises Revenue Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs https://ooc.bz/l/108998

0 · Reply

flychicken1991 Jul. 29 at 10:56 AM

$BIIB Positive (78%): shares face upward price pressure as the reported revenue and adjusted-EPS beats can prompt investors and analysts to raise near-term earnings expectations and assign greater value to Biogen’s growth portfolio. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/c002ab2de10d8bb2?utm_source=stocktwits&utm_medium=story_url

0 · Reply

StocktwitsEarnings Jul. 29 at 10:17 AM

$BIIB Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.66 down -84.76% YoY • Reported revenue of $2.74B up 3.42% YoY • Biogen expects full year 2026 Non-GAAP diluted EPS of $12.00 to $13.00, while total revenue is projected to increase by a mid-single digit percentage compared to 2025 for Biogen.

0 · Reply

LiveSquawk Jul. 29 at 10:14 AM

$BIIB Biogen Q2 2026 Earnings -Rev $2.74B (est $2.47B) -Adj EPS $3.60 (est $2.89) -Product Rev. $1.92B (est $1.77B) -Now Sees Yr Rev Increase By Mid-Single Digit Percentage -Sees FY Adj EPS $12 To $13, Saw $14.25 To $15.25

0 · Reply

TNNStockAnalysisNews Jul. 29 at 2:26 AM

Top Stocks to Watch Tomorrow - July 29, 2026 $FOMC --- 2:00 PM ET Wednesday — The Session Pivot $SKHY --- Reports Wednesday (Ground Zero of the Memory War — After CXMT’s 466% IPO) $BIIB --- Alzheimer’s Drug Commercial Ramp — The Slow But Real Recovery $SBUX --- Reports After Market Close $ARM --- Reports Wednesday - AI Chip Royalties at a Pivotal Growth Moment https://truthsandnews.com/markets/top-stocks-to-watch-tomorrow-july-29-2026-sofi-qualcomm

0 · Reply

27R Jul. 28 at 4:48 PM

$BIIB Buckle up — earnings before the open tomorrow.

0 · Reply

Market Cap	29.82B
Revenue (ttm)	9.89B
Net Income (ttm)	1.29B
EPS (ttm)	N/A
PE Ratio	14.53
Forward PE	16.05
Profit Margin	13.07%
Debt to Equity Ratio	0.39

Volume	300,085
Avg Vol	1,265,114
Day's Range	N/A - N/A
Shares Out	147.75M
Stochastic %K	53%
Beta	0.17
Analysts	Strong Sell
Price Target	$233.33